Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · IEX Real-Time Price · USD
946.87
-1.18 (-0.12%)
At close: Feb 20, 2024, 4:00 PM
948.60
+1.73 (0.18%)
After-hours: Feb 20, 2024, 5:06 PM EST
-0.12%
Market Cap 102.21B
Revenue (ttm) 13.12B
Net Income (ttm) 3.95B
Shares Out 107.94M
EPS (ttm) 34.77
PE Ratio 27.23
Forward PE 20.40
Dividend n/a
Ex-Dividend Date n/a
Volume 417,733
Open 950.00
Previous Close 948.05
Day's Range 943.73 - 963.00
52-Week Range 684.81 - 973.99
Beta 0.11
Analysts Buy
Price Target 938.83 (-0.85%)
Earnings Date Feb 2, 2024

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 2, 1991
Employees 13,450
Stock Exchange NASDAQ
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2023, REGN's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $938.83, which is a decrease of -0.85% from the latest price.

Price Target
$938.83
(-0.85% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to pl...

Other symbols: SNY
4 days ago - GlobeNewsWire

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dup...

4 days ago - GlobeNewsWire

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

14 days ago - GlobeNewsWire

Regeneron beats quarterly revenue estimates

Drug maker Regeneron beat fourth-quarter revenue estimates on Friday.

18 days ago - Reuters

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023 and provided a business up...

18 days ago - GlobeNewsWire

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authori...

18 days ago - GlobeNewsWire

2seventy bio to sell experimental cell therapies to Regeneron

Cancer treatment maker 2seventy bio will sell all its experimental cell therapies to Regeneron Pharmaceuticals for an upfront payment of $5 million and focus on its sole approved product Abecma, the t...

Other symbols: TSVT
21 days ago - Reuters

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

Regeneron to assume full development and commercialization rights for 2seventy bio's preclinical and clinical stage cell therapy pipeline Regeneron to assume full development and commercialization rig...

21 days ago - GlobeNewsWire

US FDA approves Dupixent to treat younger kids with esophageal condition

The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg, t...

Other symbols: SNY
26 days ago - Reuters

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proporti...

Other symbols: SNY
26 days ago - GlobeNewsWire

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo

26 days ago - GlobeNewsWire

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) TARRYTOWN, N.Y. and WASHINGTON , Jan. 24, 2024 /PRNewswire...

27 days ago - PRNewsWire

10 Healthcare Stocks That Are Heating Up

The sector has seen one of the best starts to the year in decades, Goldman says.

4 weeks ago - Barrons

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

Data included from first and only Phase 3 trial specifically evaluating a biologic in this difficult-to-treat population Phase 3 trial showed more than twice as many patients treated with Dupixent ach...

5 weeks ago - GlobeNewsWire

3 health care stocks off to strong starts in 2024

Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups since ...

Other symbols: AMGNGILD
5 weeks ago - MarketBeat

AI is the big thing right now, but the real tool is genetics, says Regeneron CEO Dr. Schleifer

Regeneron CEO Dr. Leonard Schleifer joins 'Mad Money' host Jim Cramer to talk cancer treatments, quarterly earnings, weight loss medication and more.

6 weeks ago - CNBC Television

Regeneron CEO: We want to retain efficacy and eliminate bad side effects with our cancer treatments

Regeneron CEO Dr. Leonard Schleifer joins 'Mad Money' host Jim Cramer to talk cancer treatments, quarterly earnings, weight loss medication and more.

6 weeks ago - CNBC Television

Regeneron CEO says the next big thing for biotech isn't AI, it's gene therapy

Regeneron CEO Leonard Schleifer detailed the biotech company's newest ventures in the pharmaceutical industry.

6 weeks ago - CNBC

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries

Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small ...

6 weeks ago - PRNewsWire

Regeneron reports preliminary Q4 U.S. sales of Eylea at $1.34 bln

Regeneron Pharmaceuticals said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.34 billion in the United States in the fourth quarter.

6 weeks ago - Reuters

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating resu...

6 weeks ago - GlobeNewsWire

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January ...

2 months ago - GlobeNewsWire

Wells Fargo's top pharma picks for 2024

Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.

Other symbols: ABBVAMGNBIIBIBBLLYVRTX
2 months ago - CNBC Television

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

TARRYTOWN, N.Y., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its inclusion on the Dow Jones Sustainability World Index (DJSI World) for the fifth c...

2 months ago - GlobeNewsWire

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR

2 months ago - GlobeNewsWire